New Insights on VASCEPA®/VAZKEPA® (icosapent ethyl) and EPA to be Presented at ESC Congress

Amarin Corporation plc (NASDAQ:AMRN), based in Dublin, Ireland and Bridgewater, New Jersey, has announced the presentation of new data from the REDUCE-IT® cardiovascular outcomes trial involving its drug VASCEPA®/VAZKEPA® (icosapent ethyl) at the European Society of Cardiology (ESC) Congress, scheduled from August 30 to September 2, 2024, in London, United Kingdom.

The REDUCE-IT trial is a pivotal study evaluating the efficacy of icosapent ethyl in reducing cardiovascular events in patients with elevated triglycerides despite statin therapy. The study's new data includes subgroup analyses and mechanistic insights into how eicosapentaenoic acid (EPA) works. These findings will be shared through various presentations during the congress.

The accepted abstracts to be presented include four main topics. The first abstract focuses on a subgroup analysis of the REDUCE-IT trial, examining if baseline levels of small dense low-density lipoprotein cholesterol (sdLDL-C) influence the effectiveness of icosapent ethyl in reducing cardiovascular events. This presentation is scheduled for August 30th and will be delivered by a team of researchers including Rahul Aggarwal, MD, and Deepak L. Bhatt, MD, MPH.

A second abstract evaluates the relationship between triglycerides and cardiovascular events in patients with either initial or recurrent acute coronary syndrome (ACS). This study aims to understand how triglyceride levels impact cardiovascular risk and will be presented on September 2nd by Alberto Cordero and colleagues.

The third abstract assesses the number of ACS patients in Spanish hospitals who are eligible for treatment with icosapent ethyl. This study provides valuable data on the potential patient population that could benefit from the drug and will also be presented by Alberto Cordero and his team on September 2nd.

The fourth abstract investigates the effects of EPA on the oxidation of lipoprotein(a) [Lp(a)] in conditions of high glucose. This study aims to shed light on the antioxidative properties of EPA and its potential benefits in cardiovascular health. The findings will be presented by Samuel C.R. Sherratt, PhD, and other researchers on September 2nd.

Nabil Abadir, MB. CH.B., the Senior Vice President and Chief Medical Officer at Amarin, emphasized the company's commitment to advancing cardiovascular research and reducing residual cardiovascular risk for patients. He stated that these new findings enhance the clinical understanding of the benefits of VASCEPA/VAZKEPA and its mechanisms of action, providing additional validation of its clinical utility.

Amarin, a leader in cardiovascular disease management, operates with offices in the United States, Ireland, Switzerland, and other European countries. The company is dedicated to improving scientific knowledge of cardiovascular risks that persist beyond traditional therapies and strives to advance treatment options worldwide.

The REDUCE-IT trial was a global study assessing the impact of VASCEPA on cardiovascular outcomes over seven years. It involved 8,179 patients across 400 clinical sites in 11 countries, with a significant number of sites in the United States. The trial was conducted under a special protocol assessment agreement with the FDA.

VASCEPA (icosapent ethyl) is a unique prescription treatment approved by the U.S. FDA for reducing cardiovascular risk in high-risk patients with elevated triglycerides despite statin therapy. Launched in the United States in January 2020, VASCEPA has been prescribed over ten million times and is covered by most major medical insurance plans. The drug is also approved in Canada, Germany, Lebanon, and the United Arab Emirates. In March 2021, icosapent ethyl received marketing authorization in the European Union under the brand name VAZKEPA for reducing cardiovascular risk in high-risk patients.

Amarin continues to invest in research and support clinical studies to broaden the understanding and application of VASCEPA/VAZKEPA, aiming to improve cardiovascular health globally.